gsk3640254
Small moleculeexperimental
Clinical trial activity
15 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
12
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 19, 2017 (NCT03231943)
Timeline
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusINHIBITOR
Human immunodeficiency virus inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04900038 | Phase 2 | Aug 18, 2021 | ViiV Healthcare |
| NCT04857892 | Phase 1 | Apr 21, 2021 | ViiV Healthcare |
| NCT04493216 | Phase 2 | Nov 16, 2020 | ViiV Healthcare |
| NCT04630002 | Phase 1 | Oct 28, 2020 | ViiV Healthcare |
| NCT04563845 | Phase 1 | Oct 21, 2020 | ViiV Healthcare |
| NCT04507321 | Phase 1 | Sep 24, 2020 | ViiV Healthcare |
| NCT04425902 | Phase 1 | Jun 16, 2020 | ViiV Healthcare |
| NCT04263142 | Phase 1 | Jan 27, 2020 | ViiV Healthcare |
| NCT04128293 | Phase 1 | Oct 8, 2019 | ViiV Healthcare |
| NCT03984825 | Phase 1 | Jun 13, 2019 | ViiV Healthcare |
| NCT03836729 | Phase 1 | Feb 11, 2019 | ViiV Healthcare |
| NCT03784079 | Phase 2 | Jan 31, 2019 | ViiV Healthcare |
| NCT03816696 | Phase 1 | Jan 23, 2019 | ViiV Healthcare |
| NCT03575962 | Phase 1 | Jun 19, 2018 | ViiV Healthcare |
| NCT03231943 | Phase 1 | Sep 19, 2017 | GlaxoSmithKline, ViiV Healthcare |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ViiV Healthcare | For profit | 15 | 15 | 2 | 2017 |
| GlaxoSmithKline | For profit | 1 | 0 | 1 | 2017 |
2 organizations
Page 1 / 1